Square Pharmaceuticals PLC. Stock

Equities

SQURPHARMA

BD0473SQPH00

Pharmaceuticals

End-of-day quote Dhaka S.E. 06:00:00 2024-05-26 pm EDT 5-day change 1st Jan Change
206.2 BDT +0.34% Intraday chart for Square Pharmaceuticals PLC. -0.05% -1.95%
Sales 2024 * 71.02B 605M Sales 2025 * 79.68B 678M Capitalization 183B 1.56B
Net income 2024 * 21.32B 181M Net income 2025 * 24.37B 207M EV / Sales 2024 * 2.57 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.29 x
P/E ratio 2024 *
8.77 x
P/E ratio 2025 *
7.5 x
Employees 12,503
Yield 2024 *
4.97%
Yield 2025 *
5.46%
Free-Float 64.82%
More Fundamentals * Assessed data
Dynamic Chart
Square Pharmaceuticals PLC. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Square Pharmaceuticals PLC. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Square Pharmaceuticals PLC. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Square Pharmaceuticals PLC. Recommends Cash Dividend for the Year Ended June 30, 2023 CI
Square Pharmaceuticals PLC Announces Contract Manufacturing Agreement with M/S Aristopharma Ltd CI
Square Pharmaceuticals Limited has Changed its Name to Square Pharmaceuticals PLC CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022 CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021 CI
Square Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2021 CI
Square Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended on June 30, 2021 CI
Square Pharmaceuticals Limited Reports Earnings Results for the Third Quarter Ended March 31, 2021 CI
Square Pharmaceuticals Limited Reports Earnings Results for the Second Quarter Ended December 31, 2020 CI
More news
1 day+0.34%
1 week-0.05%
Current month-2.23%
1 month-0.72%
3 months-5.11%
6 months-1.72%
Current year-1.95%
More quotes
1 week
203.00
Extreme 203
210.00
1 month
203.00
Extreme 203
218.00
Current year
203.00
Extreme 203
222.70
1 year
203.00
Extreme 203
222.70
3 years
203.00
Extreme 203
251.90
5 years
149.05
Extreme 149.0476
251.90
10 years
131.59
Extreme 131.5852
278.67
More quotes
Managers TitleAgeSince
Chief Executive Officer - 79-12-31
Director of Finance/CFO - -
Compliance Officer - -
Members of the board TitleAgeSince
Chief Executive Officer - 79-12-31
Chairman - 90-12-31
Director/Board Member - 90-12-31
More insiders
Date Price Change Volume
24-05-27 206.2 +0.34% 300,138
24-05-26 205.5 -0.15% 225,390
24-05-23 205.8 -0.10% 176,171
24-05-21 206 -0.15% 211,608
24-05-20 206.3 -0.15% 149,164

End-of-day quote Dhaka S.E., May 26, 2024

More quotes
Square Pharmaceuticals PLC. is a Bangladesh-based pharmaceuticals company. The main activities of the Company are to manufacture and market generic pharmaceutical products, basic chemical products, and animal health products. It is also engaged in the marketing of crop care products. It operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all live species. Its Pharma products include Ace, Ace Plus, Ace Power, Aclitol Cozycap, Adryl, Acetram, Afun, Akicin, Alacot DS Eye Drops, Alacot Eye Drops, Alacot Max Eye Drops, Alarid Eye Drops, Alarid, Alice Lotion, among others. Its Herbal and Hutraceutical products include AmCivit, Antiscar, Arubin, Betaburn, Bioprem, Bolardi, Femony, Fitvit, Flemo Max, Flemo, Flemo Plus, Freezy, Lecor, Livolite, Maximilk, Monera, Redclov, Reli Balm, Revatol, among others. Its Agrovet and crop care products include Ace-Vet Bolus, Agrizeb 80 WP, Aqua Rock, Almex-Vet Bolus and Andopan Powder.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
206.2 BDT
Average target price
321.8 BDT
Spread / Average Target
+56.04%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. SQURPHARMA Stock